Skip to main content
SpringerLink
Log in
Book cover

Medizinische Therapie 2005|2006 pp 191–194Cite as

Wirkungsweisen der antineoplastischen Chemo- und Immuntherapie

  • Chapter

  • 52 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adamson DJA, Thompson WD, Dawson AA, Bennett B, Haites NE (1995) p53 mutation and expression in lymphoma. Br J Cancer 72: 150–154

    CAS  PubMed  Google Scholar 

  • Allan N, Richards S, Shepherd P et al. (1995) UK Medical Research Council randomized multicenter trial of interferon-alpha for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 345: 1392

    Article  CAS  PubMed  Google Scholar 

  • Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particulary in relation to adjuvant systemic therapy and radiotherapy. Nature Medicine 1: 1029–1034

    Article  CAS  PubMed  Google Scholar 

  • Bosari S, Viale G, Bossi G, Maggioni M, Coggi C, Murray JJ, Lee AKC (1994) Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. Journal of National Cancer Institute 86: 681–687

    CAS  Google Scholar 

  • Colombat P, Salles G, Brousse N et al. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97: 101–106

    Article  CAS  PubMed  Google Scholar 

  • Czuczman MS, Grillo-Lopez AJ, White CA et al. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268–276

    CAS  PubMed  Google Scholar 

  • Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342–348

    Article  CAS  PubMed  Google Scholar 

  • Feuring-Buske M, Kneba M, Unterhalt M et al. (2000) IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 79: 493–500

    CAS  PubMed  Google Scholar 

  • Gjertsen MK, Gaudernack G (1998) Mutated Ras peptides as vaccines in immunotherapy of cancer. Vox Sang 74(Suppl 2): 489–495

    CAS  PubMed  Google Scholar 

  • Grant S (1998) Ara-C: cellular and molecular pharmacology. Adv Cancer Res 72: 197–233

    CAS  PubMed  Google Scholar 

  • Hamelin R, Laurent-Puig P, Olschwang S et al. (1994) Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106: 42–48

    CAS  PubMed  Google Scholar 

  • Hawkins DS, Demers GW, Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892–898

    CAS  PubMed  Google Scholar 

  • Hehlmann R, Heimpel H, Hasford J et al. (1994). Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogeneous leukemia. Blood 84: 4064–4077

    CAS  PubMed  Google Scholar 

  • Huhn D, Herrmann R (2001) Medikamentöse Therapie maligner Erkrankungen. Urban & Fischer, München Jena

    Google Scholar 

  • Lai WC, Bennett M (1998) DNA vaccines. Crit Rev Immunol 18: 449–484

    CAS  PubMed  Google Scholar 

  • Lee DJ, Corr M, Carson DA (1998) Control of immune responses by gene immunization. Ann Med 30: 460–468

    CAS  PubMed  Google Scholar 

  • Leukemia ICSGoCm (1994) Interferon alpha 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330: 820–825

    Google Scholar 

  • Leukemia ICSGoCM (1998) Long-term follow up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 92: 1541–1548

    Google Scholar 

  • Ohnishi K, Ohno R, Tomonaga M et al. (1995) A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogeneous leukemia in chronic phase. Blood 86: 906–916

    CAS  PubMed  Google Scholar 

  • Piro LD, White CA, Grillo-Lopez AJ (1999) Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 10: 655–661

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380–384

    Article  CAS  PubMed  Google Scholar 

  • Rouby SE, Thomas A, Rosenberg CR, Potmesil M, Silber R, Newcomb EW (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82: 3452–3459

    PubMed  Google Scholar 

  • Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S (1991) Mutations in p53 as potential molecular markers for human breast cancer. Proceedings of the National Academy of Sciences USA 88: 10657–10661

    CAS  Google Scholar 

  • Schofield J, Robinson W, Murphy J, Rovira D (1994) Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prologning survival in chronic myeloid leukemia. Ann Int Med 121: 736–744

    CAS  PubMed  Google Scholar 

  • Schultze JL, Gribben JG, Nadler LM (1998) Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies. Curr Opin Oncol 10: 542–547

    CAS  PubMed  Google Scholar 

  • Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T, Nordenskjold B (1992) Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369–1373

    Article  CAS  PubMed  Google Scholar 

  • Usami I, Kubota M, Bessho R, Kataoka A, Koishi S, Watanabe K, Sawada M, Lin YW, Akiyama Y, Furusho K (1998) Role of protein tyrosine phosphorylation in etoposide-induced apoptosis and NF-kappa B activation. Biochem Pharmacol 55: 185–191

    Article  CAS  PubMed  Google Scholar 

  • Wu GS, El-Deiry WS (1996) Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 2: 623–633

    CAS  PubMed  Google Scholar 

  • Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, Miyazaki I (1992) Expression of p53 protein in colorectal cancer and its re-lationship to short-term prognosis. Cancer 70: 2778–2784

    CAS  PubMed  Google Scholar 

  • Yuan ZM, Huang Y, Kraeft SK, Chen LB, Kharbanda S, Kufe D (1996) Interaction of cyclin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1-beta-D-arabinofuranosylcytosine. Oncogene 13: 939–946

    CAS  PubMed  Google Scholar 

Download references

Authors
  1. Andreas Neubauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Innere Medizin I, Klinikum der Universität Regensburg, D-93042, Regensburg

    Jürgen Schölmerich

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Heidelberg

About this chapter

Cite this chapter

Neubauer, A. (2005). Wirkungsweisen der antineoplastischen Chemo- und Immuntherapie. In: Schölmerich, J., et al. Medizinische Therapie 2005|2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27385-9_20

Download citation

  • DOI: https://doi.org/10.1007/3-540-27385-9_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21226-3

  • Online ISBN: 978-3-540-27385-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation